2008 NSTI Nanotechnology Conference and Trade Show - Nanotech 2008 - 11th Annual

Partnering Events:

TechConnect Summit
Clean Technology 2008

Manufacture and in vitro efficacy of lymphoma-targeted doxorubicin-loaded PLGA nanoparticles

J. Lu, M. Nkansah, J. Park, P.M. Fong
Carigent Therapeutics, Inc., US

NHL, doxorubicin, CD19, targeting, PLGA, nanoparticles

Carigent has developed a new surface tethering technology that can attach ligands to PLGA particles at very high density. Using this technology doxorubicin (DOX) can be encapsulated in PLGA, and targeted thus making it more efficacious than untargeted DOX particles or free drug in Non-Hodgkins lymphoma in vitro studies. Carigent’s surface tethering systems relies on the use of lipids to anchor hydrophilic avidin to the particle surface. The avidin groups can then be modified with any desired biotinylated ligand—in this case anti-CD19. The DOX loaded nanoparticles used in this study were 100 to 200 nm diameter, had a loading of 20 ug DOX per mg of PLGA, a controlled release profile that persisted for weeks, and a surface avidin density of 30 ug per mg, which was subsequently saturated with anti-CD19. MTT assay showed that the CD19 targeted particles were 25 times more effective than untargeted particles in suppressing CD19-expressing mouse B cell lymphoma A20 cells, with IC50’s of 0.1 and 2.5 uM respectively. These data suggest that Carigent’s CD19 targeted DOX-loaded nanoparticles are more efficacious than untargeted particles or free drug in treating B-cell non Hodgkins lymphoma.

Nanotech 2008 Conference Program Abstract